Featured Research

from universities, journals, and other organizations

Fasting may benefit patients with epilepsy

Date:
December 6, 2012
Source:
Johns Hopkins Medicine
Summary:
Children with persistent and drug-resistant seizures treated with the high-fat, low-carbohydrate ketogenic diet may get an added therapeutic benefit from periodic fasting, according to a small study.

Children with persistent and drug-resistant seizures treated with the high-fat, low-carbohydrate ketogenic diet may get an added therapeutic benefit from periodic fasting, according to a small Johns Hopkins Children's Center study.

The results, published online Dec. 3 in the journal Epilepsy Research, suggest the ketogenic diet and fasting can work in tandem to reduce seizures but appear do so through different mechanisms -- a finding that challenges the longstanding assumption that the two share a common mechanism.

"Our findings suggest that fasting does not merely intensify the therapeutic effects of the ketogenic diet but may actually represent an entirely new way to change the metabolism of children with epilepsy," says lead investigator Adam Hartman, M.D., a pediatric neurologist at the Johns Hopkins Children's Center.

In the study, six children, ages 2 to 7, and all on the ketogenic diet, were asked to fast on alternate days. All six children had seizure disorders incompletely resolved by the diet alone.

Four of the six children experienced between 50 percent and 99 percent fewer seizures after the fasts were added to the dietary regimen. Three of the six were able to continue the fasting regimen for two months or longer.

The Johns Hopkins investigators say while the results are preliminary, they do provide compelling evidence of the potential benefits of fasting. Periodic fasts, they add, may eventually prove to be an alternative standalone therapy in children with drug-resistant epilepsy.

The researchers caution that larger studies are needed to further elucidate the effects of fasting. They also warn that fasting should be done under the strict supervision of a pediatric neurologist.

Made up of high-fat foods and few carbohydrates, the ketogenic diet is believed to work by triggering biochemical changes that eliminate seizure-causing short circuits in the brain's signaling system. The diet, popularized in the early 1900s, was designed to mimic the physiologic effects of fasting -- a seizure-control method favored by ancient Greeks. Since then, physicians have believed that the two therapies share a common mechanism.

The new Johns Hopkins findings, however, suggest otherwise.

"We suspect that fasting affects nerve cells in a completely different manner from the ketogenic diet," Hartman says.

This hypothesis stemmed from a 2010 study of mice conducted by the Johns Hopkins team.

Two groups of epileptic mice -- one treated with the ketogenic diet and one treated with fasting -- had strikingly different responses to different seizure triggers. Animals treated with the ketogenic diet experienced fewer seizures than fasting mice when exposed to low amounts of electricity, but fared worse when they were injected with kainic acid, a potent nervous system stimulant and a known seizure trigger. Fasting mice, on the other hand, did worse when exposed to electricity but tolerated kainic acid injections far better than their ketogenic diet counterparts.

In other words, the researchers say, each therapy protected against one seizure trigger, while increasing sensitivity to the other.

"We don't fully understand the reasons for these marked differences, but unraveling the mechanisms behind them will help pave the way toward new therapies for epilepsy, and is the focus of our ongoing work," says Eric Kossoff, M.D., pediatric neurologist and director of the ketogenic diet clinic at the Johns Hopkins Children's Center.

James Rubenstein, M.D., of Johns Hopkins was co-author on the research.


Story Source:

The above story is based on materials provided by Johns Hopkins Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Adam L. Hartman, James E. Rubenstein, Eric H. Kossoff. Intermittent fasting: A “new” historical strategy for controlling seizures? Epilepsy Research, 2012; DOI: 10.1016/j.eplepsyres.2012.10.011

Cite This Page:

Johns Hopkins Medicine. "Fasting may benefit patients with epilepsy." ScienceDaily. ScienceDaily, 6 December 2012. <www.sciencedaily.com/releases/2012/12/121206203122.htm>.
Johns Hopkins Medicine. (2012, December 6). Fasting may benefit patients with epilepsy. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/12/121206203122.htm
Johns Hopkins Medicine. "Fasting may benefit patients with epilepsy." ScienceDaily. www.sciencedaily.com/releases/2012/12/121206203122.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins